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From 1
st International Congress on Neurobiology and Clinical Psychopharmacology and European
Psychiatric Association Conference on Treatment Guidance
Thessaloniki, Greece. 19-22 November 2009
This lecture considers the pharmacotherapy of depres-
sion with EPA under the following headings:
￿ Epidemiological evidence
￿ Biochemical evidence
￿ First trial of pure EPA in severe treatment-resistant
depression
￿ Subsequent randomized double-blind placebo-
controlled trials
￿ Putative mechanisms.
R e s u l t so b t a i n e df r o mo u ro w ng r o u p ,i n c l u d i n g
structural neuroimaging and 31-phosphorus neurospec-
troscopy findings, showing an association of EPA treat-
ment of depression with a marked decrease in cerebral
phosphodiesters, a marked increase in cerebral phospho-
monoesters and reduced lateral ventricular volume, will
also be presented.
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